Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Timing of HPV16-E6 antibody seroconversion before OPSCC: Findings from the HPVC3 consortium

Title: Timing of HPV16-E6 antibody seroconversion before OPSCC: Findings from the HPVC3 consortium
Authors: Kreimer, AR; Ferreiro-Iglesias, A; Nygard, M; Bender, N; Schroeder, L; Hildesheim, A; Robbins, HA; Pawlita, M; Langseth, H; Schlecht, NF; Tinker, LF; Agalliu, I; Smoller, SW; Ness-Jensen, E; Hveem, K; D'Souza, G; Visvanathan, K; May, B; Ursin, G; Weiderpass, E; Giles, GG; Milne, RL; Cai, Q; Blot, WJ; Zheng, W; Weinstein, SJ; Albanes, D; Brenner, N; Hoffman-Bolton, J; Kaaks, R; Barricarte, A; Tjønneland, A; Sacerdote, C; Trichopoulou, A; Vermeulen, RCH; Huang, WY; Freedman, ND; Brennan, P; Waterboer, T; Johansson, M
Publisher Information: OXFORD UNIV PRESS
Publication Year: 2019
Collection: The University of Melbourne: Digital Repository
Description: BACKGROUND: Human papillomavirus type 16 (HPV16)-E6 antibodies are detectable in peripheral blood before diagnosis in the majority of HPV16-driven oropharyngeal squamous cell carcinoma (OPSCC), but the timing of seroconversion is unknown. PATIENTS AND METHODS: We formed the HPV Cancer Cohort Consortium which comprises nine population cohorts from Europe, North America and Australia. In total, 743 incident OPSCC cases and 5814 controls provided at least one pre-diagnostic blood sample, including 111 cases with multiple samples. Median time between first blood collection and OPSCC diagnosis was 11.4 years (IQR = 6-11 years, range = 0-40 years). Antibodies against HPV16-E6 were measured by multiplex serology (GST fusion protein based Luminex assay). RESULTS: HPV16-E6 seropositivity was present in 0.4% of controls (22/5814; 95% CI 0.2% to 0.6%) and 26.2% (195/743; 95% CI 23.1% to 29.6%) of OPSCC cases. HPV16-E6 seropositivity increased the odds of OPSCC 98.2-fold (95% CI 62.1-155.4) in whites and 17.2-fold (95% CI 1.7-170.5) in blacks. Seropositivity in cases was more frequent in recent calendar periods, ranging from 21.9% pre-1996 to 68.4% in 2005 onwards, in those with blood collection near diagnosis (lead time 30 years (N = 24), 20-30 years (N = 148), 10-20 years (N = 228), and
Document Type: article in journal/newspaper
Language: English
ISSN: 0923-7534
Relation: NHMRC/209057; https://hdl.handle.net/11343/271508
Availability: https://hdl.handle.net/11343/271508
Rights: https://creativecommons.org/licenses/by-nc/4.0 ; CC BY-NC
Accession Number: edsbas.6CECF6E5
Database: BASE